Corbus Pharmaceuticals CRBP Stock
Corbus Pharmaceuticals Price Chart
Corbus Pharmaceuticals CRBP Financial and Trading Overview
| Corbus Pharmaceuticals stock price | 4.92 USD |
| Previous Close | 7.91 USD |
| Open | 8.24 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 1300 |
| Day's Range | 7.66 - 8.24 USD |
| 52 Week Range | 2.11 - 13.17 USD |
| Volume | 23.84K USD |
| Avg. Volume | 305.96K USD |
| Market Cap | 32.67M USD |
| Beta (5Y Monthly) | 2.421478 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.68 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 71 USD |
CRBP Valuation Measures
| Enterprise Value | 13.28M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.14705881 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.9846351 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.31 |
Trading Information
Corbus Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 2.421478 |
| 52-Week Change | -13.88% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 13.17 USD |
| 52 Week Low | 2.11 USD |
| 50-Day Moving Average | 9.31 USD |
| 200-Day Moving Average | 5.62 USD |
CRBP Share Statistics
| Avg. Volume (3 month) | 305.96K USD |
| Avg. Daily Volume (10-Days) | 22.28K USD |
| Shares Outstanding | 4.22M |
| Float | 4.2M |
| Short Ratio | 2.42 |
| % Held by Insiders | 0.31% |
| % Held by Institutions | 9.38% |
| Shares Short | 107.82K |
| Short % of Float | 2.57% |
| Short % of Shares Outstanding | 2.56% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -37.0069% |
| Return on Equity (ttm) | -130.52% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -16136826 USD |
| EBITDA | -42866164 USD |
| Net Income Avi to Common (ttm) | -50654472 USD |
| Diluted EPS (ttm) | -10.35 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 44.23M USD |
| Total Cash Per Share (mrq) | 10.49 USD |
| Total Debt (mrq) | 24.84M USD |
| Total Debt/Equity (mrq) | 150.9 USD |
| Current Ratio (mrq) | 3.194 |
| Book Value Per Share (mrq) | 3.905 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -42044056 USD |
| Levered Free Cash Flow (ttm) | -21740776 USD |
Profile of Corbus Pharmaceuticals
| Country | United States |
| State | MA |
| City | Norwood |
| Address | 500 River Ridge Drive |
| ZIP | 02062 |
| Phone | 617 963 0100 |
| Website | https://www.corbuspharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 33 |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Q&A For Corbus Pharmaceuticals Stock
What is a current CRBP stock price?
Corbus Pharmaceuticals CRBP stock price today per share is 4.92 USD.
How to purchase Corbus Pharmaceuticals stock?
You can buy CRBP shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Corbus Pharmaceuticals?
The stock symbol or ticker of Corbus Pharmaceuticals is CRBP.
Which industry does the Corbus Pharmaceuticals company belong to?
The Corbus Pharmaceuticals industry is Biotechnology.
How many shares does Corbus Pharmaceuticals have in circulation?
The max supply of Corbus Pharmaceuticals shares is 12.23M.
What is Corbus Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Corbus Pharmaceuticals PE Ratio is now.
What was Corbus Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Corbus Pharmaceuticals EPS is -3.68 USD over the trailing 12 months.
Which sector does the Corbus Pharmaceuticals company belong to?
The Corbus Pharmaceuticals sector is Healthcare.
Corbus Pharmaceuticals CRBP included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
| NASDAQ Composite Total Return I XCMP | 20257.83 USD — |
-5.96
|
— — | 20236.33 USD — | 20672.41 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
- {{ link.label }} {{link}}